• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

恰加斯病与 SARS-CoV-2 合并感染不会导致住院结局恶化。

Chagas disease and SARS-CoV-2 coinfection does not lead to worse in-hospital outcomes.

机构信息

PROSICS Barcelona, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron, 119, 08035, Barcelona, Spain.

Instituto René Rachou-FIOCRUZ Minas, Av. Augusto de Lima, 1715, Belo Horizonte, Brazil.

出版信息

Sci Rep. 2021 Oct 13;11(1):20289. doi: 10.1038/s41598-021-96825-3.

DOI:10.1038/s41598-021-96825-3
PMID:34645833
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8514447/
Abstract

Chagas disease (CD) continues to be a major public health burden in Latina America. Information on the interplay between COVID-19 and CD is lacking. Our aim was to assess clinical characteristics and in-hospital outcomes of patients with CD and COVID-19, and to compare it to non-CD patients. Consecutive patients with confirmed COVID-19 were included from March to September 2020. Genetic matching for sex, age, hypertension, diabetes mellitus and hospital was performed in a 4:1 ratio. Of the 7018 patients who had confirmed COVID-19, 31 patients with CD and 124 matched controls were included (median age 72 (64-80) years-old, 44.5% were male). At baseline, heart failure (25.8% vs. 9.7%) and atrial fibrillation (29.0% vs. 5.6%) were more frequent in CD patients than in the controls (p < 0.05). C-reactive protein levels were lower in CD patients compared with the controls (55.5 [35.7, 85.0] vs. 94.3 [50.7, 167.5] mg/dL). In-hospital management, outcomes and complications were similar between the groups. In this large Brazilian COVID-19 Registry, CD patients had a higher prevalence of atrial fibrillation and chronic heart failure compared with non-CD controls, with no differences in-hospital outcomes. The lower C-reactive protein levels in CD patients require further investigation.

摘要

恰加斯病(CD)仍然是拉丁美洲的一个主要公共卫生负担。关于 COVID-19 和 CD 之间相互作用的信息尚不清楚。我们的目的是评估患有 CD 和 COVID-19 的患者的临床特征和住院结局,并将其与非 CD 患者进行比较。连续纳入 2020 年 3 月至 9 月期间确诊的 COVID-19 患者。以性别、年龄、高血压、糖尿病和医院为基础,对 CD 患者和 COVID-19 患者进行 4:1 的遗传匹配。在 7018 例确诊 COVID-19 的患者中,纳入了 31 例 CD 患者和 124 例匹配对照(中位年龄 72(64-80)岁,44.5%为男性)。在基线时,心力衰竭(25.8%比 9.7%)和心房颤动(29.0%比 5.6%)在 CD 患者中比对照组更常见(p<0.05)。与对照组相比,CD 患者的 C 反应蛋白水平较低(55.5[35.7,85.0]比 94.3[50.7,167.5]mg/dL)。两组之间的住院管理、结局和并发症相似。在这项大型巴西 COVID-19 登记研究中,与非 CD 对照组相比,CD 患者心房颤动和慢性心力衰竭的患病率更高,但住院结局无差异。CD 患者较低的 C 反应蛋白水平需要进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa3/8514447/52497523ae89/41598_2021_96825_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa3/8514447/52497523ae89/41598_2021_96825_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa3/8514447/52497523ae89/41598_2021_96825_Fig1_HTML.jpg

相似文献

1
Chagas disease and SARS-CoV-2 coinfection does not lead to worse in-hospital outcomes.恰加斯病与 SARS-CoV-2 合并感染不会导致住院结局恶化。
Sci Rep. 2021 Oct 13;11(1):20289. doi: 10.1038/s41598-021-96825-3.
2
Impact of Cardiovascular Risk Factors and Cardiovascular Diseases on Outcomes in Patients Hospitalized with COVID-19 in Daegu Metropolitan City.心血管危险因素和心血管疾病对大邱市 COVID-19 住院患者结局的影响。
J Korean Med Sci. 2021 Jan 11;36(2):e15. doi: 10.3346/jkms.2021.36.e15.
3
Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study.中国武汉 COVID-19 合并糖尿病患者的临床特征和死亡危险因素:一项两中心回顾性研究。
Diabetes Care. 2020 Jul;43(7):1382-1391. doi: 10.2337/dc20-0598. Epub 2020 May 14.
4
Characteristics and Outcomes Among US Patients Hospitalized for Ischemic Stroke Before vs During the COVID-19 Pandemic.美国 COVID-19 大流行前后因缺血性脑卒中住院患者的特征和结局。
JAMA Netw Open. 2021 May 3;4(5):e2110314. doi: 10.1001/jamanetworkopen.2021.10314.
5
Atrial fibrillation in patients with SARS-CoV-2 infection.新型冠状病毒感染患者的心房颤动。
Med Clin (Barc). 2021 Jul 23;157(2):58-63. doi: 10.1016/j.medcli.2021.01.003. Epub 2021 Jan 28.
6
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.意大利伦巴第地区 1591 名 ICU 收治的 SARS-CoV-2 感染患者的基线特征和结局。
JAMA. 2020 Apr 28;323(16):1574-1581. doi: 10.1001/jama.2020.5394.
7
Case Report: COVID-19 and Chagas Disease in Two Coinfected Patients.病例报告:两例合并感染 COVID-19 和恰加斯病患者
Am J Trop Med Hyg. 2020 Dec;103(6):2353-2356. doi: 10.4269/ajtmh.20-1185. Epub 2020 Oct 6.
8
Atrial fibrillation is an independent predictor for in-hospital mortality in patients admitted with SARS-CoV-2 infection.心房颤动是因感染 SARS-CoV-2 而住院的患者院内死亡率的独立预测因子。
Heart Rhythm. 2021 Apr;18(4):501-507. doi: 10.1016/j.hrthm.2021.01.018. Epub 2021 Jan 22.
9
Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19.COVID-19 住院患者静脉血栓栓塞症抗凝治疗趋势。
JAMA Netw Open. 2021 Jun 1;4(6):e2111788. doi: 10.1001/jamanetworkopen.2021.11788.
10
Predictors of mortality, ICU hospitalization, and extrapulmonary complications in COVID-19 patients.COVID-19 患者的死亡率、重症监护病房住院率和肺外并发症的预测因素。
Infect Dis Now. 2021 Sep;51(6):518-525. doi: 10.1016/j.idnow.2021.07.002. Epub 2021 Jul 7.

引用本文的文献

1
Cardiovascular Statistics - Brazil 2023.心血管统计数据 - 巴西2023年
Arq Bras Cardiol. 2024 Feb;121(2):e20240079. doi: 10.36660/abc.20240079.
2
SBC Guideline on the Diagnosis and Treatment of Patients with Cardiomyopathy of Chagas Disease - 2023.巴西心脏病学会2023年恰加斯病心肌病患者诊断与治疗指南
Arq Bras Cardiol. 2023 Jun 26;120(6):e20230269. doi: 10.36660/abc.20230269.
3
Co-infection of COVID-19 and parasitic diseases: A systematic review.新型冠状病毒肺炎与寄生虫病的合并感染:一项系统综述。

本文引用的文献

1
ABC-SPH risk score for in-hospital mortality in COVID-19 patients: development, external validation and comparison with other available scores.COVID-19患者院内死亡的ABC-SPH风险评分:开发、外部验证及与其他现有评分的比较
Int J Infect Dis. 2021 Sep;110:281-308. doi: 10.1016/j.ijid.2021.07.049. Epub 2021 Jul 24.
2
Clinical characteristics and outcomes of patients hospitalized with COVID-19 in Brazil: Results from the Brazilian COVID-19 registry.巴西新冠肺炎住院患者的临床特征与转归:巴西新冠肺炎登记处的结果
Int J Infect Dis. 2021 Jun;107:300-310. doi: 10.1016/j.ijid.2021.01.019. Epub 2021 Jan 12.
3
COVID-19: Implications for People with Chagas Disease.
Parasite Epidemiol Control. 2023 May;21:e00299. doi: 10.1016/j.parepi.2023.e00299. Epub 2023 Mar 30.
4
Editorial: Intensive management of cardiovascular disease patients with confirmed or suspected COVID-19 in area where Chagas disease is endemic.社论:在恰加斯病流行地区对确诊或疑似COVID-19的心血管疾病患者进行强化管理。
Front Med (Lausanne). 2023 Mar 3;10:1167877. doi: 10.3389/fmed.2023.1167877. eCollection 2023.
5
Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors.严重 COVID-19 的风险因素:宿主、病毒和环境因素的综述。
Viruses. 2023 Jan 7;15(1):175. doi: 10.3390/v15010175.
6
Re: "Challenges of addressing neglected tropical diseases amidst the COVID-19 pandemic in Africa: A case of Chagas Disease".关于:“非洲新冠疫情期间应对被忽视热带病的挑战:以恰加斯病为例”。
Ann Med Surg (Lond). 2022 Nov;83:104804. doi: 10.1016/j.amsu.2022.104804. Epub 2022 Oct 31.
7
Deaths Related to Chagas Disease and COVID-19 Co-Infection, Brazil, March-December 2020.2020 年 3 月至 12 月巴西因克氏锥虫病和 COVID-19 合并感染导致的死亡。
Emerg Infect Dis. 2022 Nov;28(11):2285-2289. doi: 10.3201/eid2811.212158. Epub 2022 Sep 28.
8
Management of Cardiovascular Disease in Patients With COVID-19 and Chronic Chagas Disease: Implications to Prevent a Scourge Still Larger.新冠病毒病合并慢性恰加斯病患者的心血管疾病管理:预防更大灾难的启示
Front Med (Lausanne). 2022 Jun 29;9:910388. doi: 10.3389/fmed.2022.910388. eCollection 2022.
9
Impact of COVID-19 In-hospital Mortality in Chagas Disease Patients.新冠病毒病对恰加斯病患者院内死亡率的影响
Front Med (Lausanne). 2022 May 9;9:880796. doi: 10.3389/fmed.2022.880796. eCollection 2022.
10
Sex Differences in Cardiac Pathology of SARS-CoV2 Infected and Co-infected Mice.感染 SARS-CoV-2 及合并感染的小鼠心脏病理学中的性别差异。
Front Cardiovasc Med. 2022 Mar 11;9:783974. doi: 10.3389/fcvm.2022.783974. eCollection 2022.
新型冠状病毒肺炎:对恰加斯病患者的影响。
Glob Heart. 2020 Oct 13;15(1):69. doi: 10.5334/gh.891.
4
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19.COVID-19 中的免疫、内皮损伤和补体诱导的凝血异常。
Nat Rev Nephrol. 2021 Jan;17(1):46-64. doi: 10.1038/s41581-020-00357-4. Epub 2020 Oct 19.
5
Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia.严重的新冠肺炎感染患者在接受免疫抑制治疗后出现了旋毛虫感染。
Infection. 2021 Jun;49(3):539-542. doi: 10.1007/s15010-020-01522-4. Epub 2020 Sep 10.
6
Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score.利用 ISARIC WHO 临床特征协议对因 COVID-19 住院的患者进行风险分层:4C 死亡率评分的制定和验证。
BMJ. 2020 Sep 9;370:m3339. doi: 10.1136/bmj.m3339.
7
Case Report: Disseminated Strongyloidiasis in a Patient with COVID-19.病例报告:COVID-19 患者合并播散性粪类圆线虫病。
Am J Trop Med Hyg. 2020 Oct;103(4):1590-1592. doi: 10.4269/ajtmh.20-0699.
8
Guidelines for the pharmacological treatment of COVID-19. The task-force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology.新型冠状病毒肺炎的药物治疗指南。巴西重症监护医学协会、巴西传染病学会以及巴西肺脏病与胸科学会的工作组/共识指南。
Rev Bras Ter Intensiva. 2020 Jun;32(2):166-196. doi: 10.5935/0103-507x.20200039. Epub 2020 Jul 13.
9
Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management.识别 COVID-19 相关心肌炎:可能的病理生理学及诊断和管理建议指南。
Heart Rhythm. 2020 Sep;17(9):1463-1471. doi: 10.1016/j.hrthm.2020.05.001. Epub 2020 May 5.
10
COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.COVID-19 与心血管系统:对风险评估、诊断和治疗选择的影响。
Cardiovasc Res. 2020 Aug 1;116(10):1666-1687. doi: 10.1093/cvr/cvaa106.